Case Report
Copyright ©The Author(s) 2022.
World J Clin Cases. Mar 6, 2022; 10(7): 2268-2274
Published online Mar 6, 2022. doi: 10.12998/wjcc.v10.i7.2268
Table 1 Imaging, duodenal endoscopy and biopsy, laboratory, pathological and immunohistochemical examinations of 4 patients.
Serial number
Image
Duodenal endoscopy and biopsy
Tumor markers
Ratio (%); ADC:NEN
Immunohisto-chemistry
Ki-67
Patient 1Enhanced CTNoCA19-9 rise; CEA, AFP normal30:70Component (NEN): CgA(-), Syn(+), CD56(+)30%
Patient 2Enhanced MRIYes, ADCCA19-9, CEA, AFP normal60:40Component (NEN): CgA(+), Syn(+), CD56(+)50%
Patient 3Enhanced MRIYes, ADCCA19-9 rise; CEA, AFP normal60:40Component (NEN): CgA(+/-), Syn(+), CD56(+)70%
Patient 4Enhanced CTNoCA19-9, CEA, AFP normal40:60Component (NEN): CgA(-), Syn(+), CD56(+)70%
Table 2 Treatment and follow-up data of 4 patients
Serial number
Sex
Age
First symptoms
Treatment
Chemo-therapy
Follow-up
Postoperative overall survival (mo)
Patient 1Male81JaundicePancreatico-duodenectomy NoDeath1
Patient 2Male69JaundicePancreatico-duodenectomy YesDeath29
Patient 3Male67Abdominal painPancreatico-duodenectomyYesDeath22
Patient 4Male72Jaundice;Abdominal painPancreatico-duodenectomyYesSurvival-